Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -107.09% | 2,738.91% | -263.89% | -74.20% | 205.26% |
| Total Depreciation and Amortization | -95.83% | -13.12% | -32.42% | -7.10% | -52.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.71% | -1,963.00% | -33.25% | 433.50% | -109.15% |
| Change in Net Operating Assets | 96.98% | -1,001.18% | 414.77% | 88.17% | -1,397.77% |
| Cash from Operations | -892.31% | -114.56% | 366.42% | 108.92% | -263.73% |
| Capital Expenditure | 100.00% | 30.77% | 18.75% | 88.65% | -71.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -75.39% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -92.89% | -- | -- | -- | -- |
| Other Investing Activities | -1,815.09% | -- | -- | -- | -- |
| Cash from Investing | -159.33% | 670,561.54% | 18.75% | -100.93% | 128.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.99% | -2,685,166.67% | 160.00% | -25.00% | 75.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 33.33% | 0.00% | 67.57% | -164.29% | 87.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | 100.00% | -- | -- |
| Cash from Financing | 99.98% | -954,533.33% | 89.77% | -1,860.00% | 103.94% |
| Foreign Exchange rate Adjustments | 96.12% | -228.64% | -30.28% | 1,717.24% | 95.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,656.86% | -113.68% | 239.16% | 113.95% | -196.83% |